Surgical resection is the mainstay of gastric or gastroesophageal junction cancer treatment and has curative potential for patients with early-stage disease. In order to improve the poor survival rates, there are two complementary treatment strategies used at most - perioperative chemotherapy based on UK Magic trial or adjuvant chemoradiation based on INT-0116 trial. Daily treatment decision making should be led also by institutional experiences with toxicity evaluation. We evaluated survival and toxicity outcomes of 47 consecutive patients who underwent adjuvant chemoradiation in our institution in the years 2006-2009. 45Gy in 5 weeks with concurrent two cycles of FUFA Mayo regimen chemotherapy were administrated as part of combined treatment. The acute toxicity was relatively mild (CTCAE scale): grade 2 nausea in 26%, vomiting in 13%, and diarrhoea grade 1 in 15% and general abdominal discomfort in 57% of patients. Grade 3 haematological and infectious complications in 6% and 2% respectively. Late adverse events were as follows: grade 1 esophageal toxicity in 17%, signs of mild chronic esophageal ulceration and esophageal stenosis in 9% of patients (50% of them had tracheoesophageal fistula). The Kaplan- Meier estimate of the median overall survival was 30.5 months with median 25.7 months disease free survival. The overall survival was statistically significantly affected by the amount of removed positive lymph nodes. For the proper evaluation of radiotherapy role in multimodal treatment approach, results of other clinical trials investigating role of concurrent radiotherapy in administration of perioperative chemotherapy will be necessary. Meanwhile, two equally approaches are possible, all having their pros and cons. Institutional toxicity evaluation is recommended in order to provide the best care possible.

• MeSH
• adjuvantní chemoradioterapie * škodlivé účinky   MeSH
• časové faktory MeSH
• dospělí MeSH
• gastroezofageální junkce * MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory jícnu mortalita   terapie   MeSH
• nádory žaludku mortalita   terapie   MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

• MeSH
• B-buněčný lymfom farmakoterapie   radioterapie   MeSH
• dávka záření MeSH
• lidé MeSH
• methotrexát aplikace a dávkování   škodlivé účinky   terapeutické užití   MeSH
• nádory centrálního nervového systému klasifikace   radioterapie   MeSH
• protokoly antitumorózní kombinované chemoterapie terapeutické užití   MeSH
• radioterapie metody   škodlivé účinky   využití   MeSH
• Check Tag
• lidé MeSH

• MeSH
• antitumorózní látky škodlivé účinky   MeSH
• chemorezistence MeSH
• finanční podpora výzkumu jako téma MeSH
• hematopoéza účinky léků   MeSH
• hodnocení rizik MeSH
• lithium aplikace a dávkování   škodlivé účinky   MeSH
• neutropenie chemicky indukované   prevence a kontrola   MeSH
• progrese nemoci MeSH
• Publikační typ
• techniky in vitro MeSH